Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Ghulam Rehman MohyuddinMuhammad AzizAlec BrittLee WadeWeijing SunJoaquina BarandaRaed Al-RajabiAnwaar SaeedAnup Kasi Loknath KumarPublished in: BMC cancer (2020)
Our meta-analysis and systematic review of the literature indicates similar response rates of PARPi therapy in patients with somatic and germline BRCA mutations. Investigation of use of PARPi therapy in a broader patient population, and the inclusion of somatic BRCA mutations in further clinical trials is paramount in improving therapeutic options for our patients.
Keyphrases
- systematic review
- meta analyses
- clinical trial
- dna repair
- end stage renal disease
- copy number
- ejection fraction
- chronic kidney disease
- dna damage
- breast cancer risk
- prognostic factors
- peritoneal dialysis
- case report
- randomized controlled trial
- gene expression
- dna methylation
- oxidative stress
- bone marrow
- cell therapy
- replacement therapy
- double blind